Pharmacotherapy of Cachexia

ISBN-13: 9780849333798 / Angielski / Twarda / 2005 / 608 str.

Karl G. Hofbauer; Karl G. Hofbauer; Stefan Anker

Opis

Although a wealth of information can be found scattered throughout periodicals and research papers, tracking down the most effective treatment for a heterogeneous syndrome such as cachexia can be problematic. Edited by experts in the field, with contributions from a multidisciplinary panel, Pharmacotherapy of Cachexia is the first book devoted solely to the treatment of cachexia with a focus on pharmacotherapeutic aspects.
The book discusses the various aspects of the syndrome and compares and contrasts its diverse treatment options. It explores the topic from a theoretical and practical perspective and provides an overview of currently available and future treatment. The first half of the book includes coverage of pathophysiology, associated diseases, and general therapeutic aspects. The subsequent sections devoted to pharmacotherapy cover drugs in clinical use, drugs in research and development, and the final section focuses on potential future advancements.
Numerous internationally recognized specialists have contributed chapters on the various aspects of cachexia to this book. Their critical evaluation of pathophysiological mechanisms, clinical features, and therapeutic options make it a valuable source of information on all aspects of this serious and life-threatening condition. Expert editorial guidance ensures minimal repetition of information and uniform presentation. Addressing the multiple disease processes associated with cachexia in an organized and useful way, the book is a comprehensive reference for the management of this recalcitrant and hard-to-treat syndrome.

Spis treści

PATHOPHYSIOLOGY OF CACHEXIAMalnutrition and Cachexia, C.G. Goncalves, A.L.C. Campos, J.C.U. Coelho, S. Suzuki, and M.M. MeguidAnorexia: Central and Peripheral Mechanisms, S. Perboni, G. Mantovani, A. Inui, and Y. TakimotoSkeletal Muscle Atrophy and Hypertrophy, D.J. GlassSkeletal Muscle Apoptosis in Cachexia and Aging, A.J. Dirks and C. LeeuwenburghNeurohormonal Factors, A.L. ClarkCytokines and the Pathophysiology of Skeletal Muscle Atrophy, V.E. BaracosDISEASES ASSOCIATED WITH CACHEXIADiseases Associated with Cachexia: Cancer, R.J.E. Skipworth, M. Dahele, and K.C.H. FearonCachexia Associated with AIDS, K. Berneis and K. UtechRheumatoid Cachexia, L.A. ColemanChronic Kidney Disease, B. Lindholm, J. Axelsson, O. Heimbürger, A.R. Qureshi, T. Cederholm, and P. StenvinkelCardiac Failure, P.A. Poole-WilsonChronic Obstructive Pulmonary Disease, A.M.W.J. ScholsCachexia in Older Persons, J.E. MorleyGENERAL THERAPEUTIC ASPECTSTreatment Goals, A.J.S. CoatsNutritional Treatment of Cachexia, C. Falconnier and U. KellerDRUGS IN CLINICAL USEAppetite Stimulants, M. JohnCardiac Cachexia - Drugs in Clinical Use, S. Strassburg and S.D. Ankerß2-Adrenergic Agonists in the Treatment of Muscle Atrophy, C.P. Lambert, E.Y. Uc, and W.J. EvansAndrogens, Anabolic Steroids, and Glucocorticoids, L. Harle, S. Basaria, and A.S. DobsGrowth Hormone, P.V. CarrollAnti-Inflammatory Agents in Cancer Cachexia, M.P. DavisDRUGS IN RESEARCH AND DEVELOPMENTThe Yin and Yang of IGF-1 and Ghrelin, R.G. ClarkErythropoietin -A Novel Therapeutic Option for Cachectic Patients, P. Ponikowski, E.A. Jankowska, and W. BanasiakStatins, S. von Haehling and S.D. AnkerXanthine Oxidase Inhibitors and Insulin Sensitizers, W. DoehnerTumor Necrosis Factor Inhibitors in the Management of Cancer-Associated Weight Loss Syndrome, S. Patiyil and A. JatoiFUTURE DRUG TARGETSCentral Pharmacological Targets, D.L. MarksThe Ubiquitin-Proteasome Pathway, M. BrinkPeripheral Signaling Pathways Involved in Muscle Loss, S. Possekel, T. Meier, and M.A. RueggPerspectives and Outlook, K.G. Hofbauer, S.D. Anker, A. Inui, and J.R. Nicholson

O autorze

Karl G. Hofbauer, Stefan D. Anker, Akio Inui, Janet R. Nicholson